Related Experiment Video

Updated: Jun 25, 2026

An Immunohistopathologic Study to Profile the Folate Receptor Beta Macrophage and Vascular Immune Microenvironment in Giant Cell Arteritis
06:35

An Immunohistopathologic Study to Profile the Folate Receptor Beta Macrophage and Vascular Immune Microenvironment in Giant Cell Arteritis

Published on: February 8, 2019

[Current therapeutic options for giant cell arteritis]

E Wipfler-Freissmuth1, J Loock, F Moosig

  • 1Abteilung für Innere Medizin, A. ö. KH der Elisabethinen, Völkermarkter Str. 15-19, 9020 Klagenfurt am Wörthersee, Osterreich. edith.wipfler@gmx.net

Zeitschrift Fur Rheumatologie
|February 19, 2009
PubMed

Insights

Giant cell arteritis, a common large vessel vasculitis, is typically treated with glucocorticoids. To minimize steroid toxicity, adding disease-modifying antirheumatic drugs like methotrexate is recommended.

Area of Science:

  • Rheumatology
  • Immunology
  • Internal Medicine

Context:

  • Giant cell arteritis (GCA) is the most prevalent systemic vasculitis, primarily impacting large and medium-sized arteries.
  • Current GCA therapy relies heavily on glucocorticoids, which are associated with significant long-term adverse effects.

Purpose:

  • To explore therapeutic strategies for giant cell arteritis aimed at reducing glucocorticoid dependency.
  • To evaluate the role of disease-modifying antirheumatic drugs (DMARDs) as adjuncts to glucocorticoid therapy in GCA.

Summary:

  • Glucocorticoids are the cornerstone of giant cell arteritis treatment.
  • The European League Against Rheumatism (EULAR) recommends incorporating DMARDs to mitigate glucocorticoid dosage and associated toxicities.
  • Methotrexate is the most studied DMARD for GCA, with azathioprine, tumor necrosis factor-alpha inhibitors, and cyclophosphamide as potential alternatives.

Impact:

  • This approach aims to improve patient outcomes by reducing the cumulative burden of glucocorticoid-induced side effects.
  • Identifying effective DMARDs can lead to more personalized and safer treatment regimens for giant cell arteritis patients.
  • Optimizing GCA management through steroid-sparing strategies is crucial for long-term patient well-being and disease control.

More Related Videos

Preliminary Study on Acupuncture Combined with Grain-sized Moxibustion for Treating Rheumatoid Arthritis with Finger Joint Pain04:50

Preliminary Study on Acupuncture Combined with Grain-sized Moxibustion for Treating Rheumatoid Arthritis with Finger Joint Pain

Published on: May 16, 2025

Related Concept Videos

Peripheral Artery Disease III: Interprofessional Care01:27

Peripheral Artery Disease III: Interprofessional Care

Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids01:21

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2 (COX-2),...
Myocarditis III: Medical Management01:14

Myocarditis III: Medical Management

Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...